StockData
ZBIONasdaqPharmaceutical PreparationsFiscal year ends December 31

Zenas BioPharma, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$26.71+1.87 (+7.53%)

Close on Oct 19, 2026

Market cap
$1.69B
P/E (TTM)
–
Dividend yield
–

SEC filings

30 of Zenas BioPharma's most recent filings on SEC EDGAR

DocumentFormPeriodFiledSource
Current report8-KOct 12, 2026Oct 13, 2026SEC EDGAR
Quarterly report10-QJun 30, 2026Aug 13, 2026SEC EDGAR
Current report8-KAug 12, 2026Aug 13, 2026SEC EDGAR
Quarterly report10-QMar 31, 2026May 13, 2026SEC EDGAR
Current report8-KMay 11, 2026May 13, 2026SEC EDGAR
Current report8-KMar 26, 2026Mar 31, 2026SEC EDGAR
Proxy statementDEF 14AMay 11, 2026Mar 16, 2026SEC EDGAR
Annual report10-KDec 31, 2025Mar 16, 2026SEC EDGAR
Current report8-KMar 16, 2026Mar 16, 2026SEC EDGAR
Current report8-KFeb 10, 2026Feb 13, 2026SEC EDGAR
Current report8-KJan 5, 2026Jan 5, 2026SEC EDGAR
Current report8-KDec 10, 2025Dec 15, 2025SEC EDGAR
Quarterly report10-QSep 30, 2025Nov 12, 2025SEC EDGAR
Current report8-KNov 12, 2025Nov 12, 2025SEC EDGAR
Current report8-KOct 27, 2025Oct 27, 2025SEC EDGAR
Current report8-KOct 7, 2025Oct 8, 2025SEC EDGAR
Current report8-KSep 2, 2025Sep 2, 2025SEC EDGAR
Quarterly report10-QJun 30, 2025Aug 12, 2025SEC EDGAR
Current report8-KAug 12, 2025Aug 12, 2025SEC EDGAR
Current report8-KJun 10, 2025Jun 12, 2025SEC EDGAR
Current report8-KJun 4, 2025Jun 4, 2025SEC EDGAR
Quarterly report10-QMar 31, 2025May 15, 2025SEC EDGAR
Current report8-KMay 15, 2025May 15, 2025SEC EDGAR
Proxy statementDEF 14AJun 10, 2025Apr 28, 2025SEC EDGAR
Annual report10-KDec 31, 2024Mar 11, 2025SEC EDGAR
Current report8-KFeb 5, 2025Feb 5, 2025SEC EDGAR
Current report8-KDec 2, 2024Dec 2, 2024SEC EDGAR
Quarterly report10-QSep 30, 2024Nov 12, 2024SEC EDGAR
Current report8-KNov 12, 2024Nov 12, 2024SEC EDGAR
Current report8-KSep 16, 2024Sep 16, 2024SEC EDGAR